Interestingly, PARPi at these concentrations did not exhibit cytotoxic activity in liver cancer cells such as SNU-449 and PLC/PRF/5, highlighting the heterogeneity in drug response among liver cancer subtypes [19]. Here, HSPG2 is linked to liver cancer.